Desimmie Belete A
Katholieke Universiteit Leuven, Lab Moleculaire Virologie & Gentherapie, Kapucijnenvoer 33, Leuven, Belgium.
IDrugs. 2010 Sep;13(9):622-5.
The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).
在维也纳举行的2010年第十八届国际艾滋病大会涵盖了HIV治疗领域新治疗进展的相关主题。本会议报告重点介绍了关于新型HIV进入抑制剂、逆转录酶抑制剂、整合酶抑制剂的精选报告，以及一项基于核苷类逆转录酶抑制剂的抗病毒、限制超激活疗法的临床试验数据。所讨论的研究药物包括GSK-1349572（维泰克医疗/盐野义制药株式会社）和VS-411（ViroStatics）。
